Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency

Kidney International

Volumn 61, Issue 4, 2002, Pages 1495-1501

  Haubitz, Marion ^a,b   Bohnenstengel, Frank ^c   Brunkhorst, Reinhard ^c   Schwab, Matthias ^c   Hofmann, Ute ^c   Busse, Dagmar ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c NONE

Author keywords

Cytotoxicity; Hemodialysis; Immunosuppression; Intravenous pulse therapy; Renal insufficiency; Systemic lupus erythematosus

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DIALYSATE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG PULSE THERAPY; DRUG URINE LEVEL; FEMALE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; PRIORITY JOURNAL; URINARY EXCRETION;

EID: 0036226436     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00279.x     Document Type: Article

References (27)

1. Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs
2. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement
3. Clinical pharmacokinetics of cyclophosphamide
4. Clinical pharmacokinetics of cyclophosphamide
5. Dose escalation of cyclophosphamide in patients with breast cancer: Consequences for pharmacokinetics and metabolism
6. Metabolism and pharmacokinetics of oxazaphosphorines
7. Clinical pharmacology of cyclophosphamide
8. The disposition of cyclophosphamide in a group of myeloma patients
9. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites
10. Pharmacokinetics of cyclophosphamide in renal failure
11. Clearance and recovery calculations in hemodialysis: Application to plasma, red blood cells, and dialysate measurements for cyclophosphamide
12. Hemodialysis during cyclophosphamide treatment
13. Einfluβ von leberparenchymschäden, niereninsuffiienz und Hämodialyse auf die pharmakokinetik von cyclophosphamid und seinen aktivierten metaboliten. Arzneimittel-forsch
14. The 1982 revised criteria for the classification of systemic lupus erythematosus
15. Fractionated administration of high-dose cyclophosphamide: Influence on dose-dependent changes in pharmacokinetics and metabolism
16. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: Response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines
17. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin
18. The biotransformation of cyclophosphamide in man: Influence of prednisone
19. Effect of steroid hormone on activation of endoxan (cyclophosphamide)
20. Enzymatic metabolism of cyclophosphamide and nicotine and production of a toxic cyclophosphamide metabolite
21. 14C)cyclophosphamide and its radioactive metabolites in rats pretreated with prednisolone
22. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer
23. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics
24. Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure
25. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation
26. Optimization of cyclophosphamide therapy in systemic vasculitis
27. Damage occurs early in systemic vasculitis and is an index of outcome